Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen AG Sells Service Business

Published: Tuesday, July 02, 2013
Last Updated: Tuesday, July 02, 2013
Bookmark and Share
Protagen AG, Dortmund, divested its 100% subsidiary Protagen Protein Services GmbH (PPS), to Zukunftsfond Heilbronn.

The company was spun out in January 2012 and continued the business of the former operational division Protein Services, which accumulated unique expertise in the GMP-compliant protein analytics over the years.

“The sale of this profitable service business to a potent investor with complementary portfolio companies secures a sustainable growth for PPS, an internationally renowned specialist for protein characterization and biosimilar comparability. On the other hand, the capital injection generated by this transaction is a solid mid-term financing opportunity for the Protagen strategy in the area of novel diagnostics, i.e. Dx and CDx, and enables to start the development of own products for this growing market immediately. With this step, Protagen positions itself as highly attractive target for new VC investors”, states Dr. Stefan Müllner, CEO.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protagen, Inova Announce Agreement for BICD2 Biomarker
The license agreement will allow Inova to add the novel biomarker to their portfolio of CTD reagents to help improve diagnosis of this debilitating disease.
Friday, August 12, 2016
Protagen Announces CE Mark for its Proprietary Multilisa® BICD2 Test
BICD2 is the first proprietary biomarker discovered by Protagen employing the SeroTag® technology platform, and provides significant added value to standard diagnostics for Systemic Sclerosis (SSc).
Thursday, June 16, 2016
Protagen Launches First CE Marked Diagnostic Assays
Protagen AG has announced the launch of its first CE marked diagnostic assays Multilisa® CENP-B and Multilisa® Scl-70 ELISA to aid in the diagnosis of Systemic Sclerosis (SSc).
Wednesday, June 01, 2016
Using Biomarkers to Identify Inflammation in Prostate Cancer Patients
Discovery of new biomarkers for chronic inflammation could allow the development of new, more accurate prostate cancer diagnostics.
Wednesday, March 30, 2016
Novel Route to Serum Based Prostate Cancer Diagnostics
Protagen AG has announced the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.
Thursday, February 11, 2016
Protagen AG Joins RA-MAP Consortium
Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has announced that it will join the RA-MAP Consortium.
Thursday, January 21, 2016
Protagen AG Establishes Scientific Advisory Board
Protagen AG, technology leader in the development of novel molecular diagnostics and companion diagnostic concepts for autoimmune diseases, has announced the formation of its Scientific Advisory Board (SAB).
Friday, December 11, 2015
Protagen AG Joins MATURA Consortium
Consortium to support identification of treatment response predictors in Rheumatoid Arthritis (RA).
Wednesday, December 02, 2015
Protagen, Mikrogen Collaborate
Protagen and Mikrogen have agreed on a co-development program for a new diagnostic assay to distinguish between previously infected, seropositive individuals, from newly infected patients with active Lyme disease.
Friday, November 13, 2015
Protagen AG Appoints New Board Members
New members expand expertise in diagnostics commercialization.
Monday, October 05, 2015
Protagen AG Achieves ISO 13485 Certification
The ISO 13485 certification covers the development, production and distribution of in-vitro diagnostics (IVD) for autoimmune diseases.
Wednesday, June 24, 2015
Protagen AG Appoints Bernhard Kirschbaum as New Board Member
Announcement follows recent strategic partnership between Protagen and Qiagen.
Thursday, January 08, 2015
Protagen Successfully Closes New Financing Round
QIAGEN N.V. joins existing investors.
Tuesday, December 16, 2014
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen Raises € 10.0 Million for Diagnostic Developments
Funds will be utilized for the targeted expansion of the business unit Diagnostics and the clinical validation of proprietary diagnostic marker proteins.
Thursday, September 09, 2010
Scientific News
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
IMM Uses Nanowizard® to Evaluate Cardiovascular Disease Risk
JPK Instruments reports on the use of their NanoWizard® AFM system at the Instituto de Medicina Molecular at the University of Lisbon.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Zika Reference Strain Sequenced
An international research team has sequenced a strain of Zika for use as a WHO reference strain.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!